VistaGen Therapeutics Granted U.S. Patent regarding Methods

New Post Public Reply Private Reply Replies (0) Message Board

News Desk 2018

Dec 6, 2017 at 11:00 PM 49

VistaGen Therapeutics Granted U.S. Patent regarding Methods of Production for AV-101

SOUTH SAN FRANCISCO, CA --(Marketwired - December 06, 2017) - VistaGen Therapeutics Inc. ( NASDAQ : VTGN ), a clinical-stage biopharmaceutical company focused on developing new generation medicines for depression and other central nervous system (CNS) disorders, today announced the U.S. Patent and Trademark Office (USPTO) has issued U.S. Patent No. 9,834,801 related to certain methods of production for AV-101, VistaGen's lead CNS product candidate.

"The issuance of this U.S. patent by the USPTO advances our intellectual property strategy for AV-101 at this vital period in its clinical development. This issued U.S. patent, in conjunction with the potential issuance of additional AV-101 patent applications currently under review worldwide, provides VistaGen with added long-term intellectual property protection for AV-101 and enhances its commercial potential," stated Shawn Singh, Chief Executive Officer of VistaGen .

About VistaGen

VistaGen Therapeutics, Inc. ( NASDAQ : VTGN ) is a clinical-stage biopharmaceutical company focused on developing new generation medicines for depression and other CNS disorders. VistaGen's lead CNS product candidate, AV-101, is in Phase 2 development, initially as a new generation oral antidepressant drug candidate for major depressive disorder (MDD). AV-101's mechanism of action is fundamentally different from all FDA-approved antidepressants and atypical antipsychotics used adjunctively to treat MDD, with potential to drive a paradigm shift towards a new generation of safer and faster-acting antidepressants. AV-101 is currently being evaluated by the National Institute of Mental Health (NIMH) in a small Phase 2 monotherapy study in MDD being fully funded by the NIMH and conducted by Dr. Carlos Zarate Jr., Chief, Section on the Neurobiology and Treatment of Mood Disorders and Chief of Experimental Therapeutics and Pathophysiology Branch at the NIMH. VistaGen is preparing to launch a 180-patient Phase 2 study of AV-101 as an adjunctive treatment for MDD patients with an inadequate response to standard, FDA-approved antidepressants, with Dr. Maurizio Fava of Harvard University as Principal Investigator. AV-101 may also have the potential to treat multiple CNS disorders and neurodegenerative diseases in addition to MDD, including neuropathic pain, epilepsy, Huntington's disease, Parkinson's disease levodopa-induced dyskinesia and other disorders where modulation of the NMDA receptors, activation of the AMPA neurotransmitter pathways and/or key active metabolites of AV-101 may achieve therapeutic benefit.

For more information, please visit www.vistagen.com and connect with VistaGen on Twitter , LinkedIn and Facebook .

Forward-Looking Statements

The statements in this press release that are not historical facts may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Those risks and uncertainties include, but are not limited to, risks related to securing sufficient funding for, and the launch, continuation and results of the NIMH's Phase 2 (monotherapy) and/or the Company's planned Phase 2 (adjunctive treatment) clinical studies of AV-101 in MDD, and other CNS diseases and disorders, including neuropathic pain and PD LID, allowance of patent applications and continued protection of its intellectual property, and the availability of substantial additional capital to support its operations, including the AV-101 Phase 2 adjunctive treatment study and other potential AV-101 clinical development activities described above. These and other risks and uncertainties are identified and described in more detail in VistaGen's filings with the Securities and Exchange Commission (SEC). These filings are available on the SEC's website at www.sec.gov . VistaGen undertakes no obligation to publicly update or revise any forward-looking statements.

Company Contact Mark A. McPartland VistaGen Therapeutics Inc. Phone: +1 (650) 577-3600 Email: IR@vistagen.com Investor Contact: Valter Pinto / Allison Soss KCSA Strategic Communications Phone: +1 (212) 896-1254/+1 (212) 896-1267 Email: VistaGen@KCSA.com

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

2026 Beauty Icon Awards: Honoring Black Beauty Excellence

When it comes to honoring legacy and future within the Black beauty industry, the 2026 Beauty Icon Awards seem ready to steal the spotlight. Set to take place on October 10th at Atlanta's Riverside EpiCenter, this gathering is more than just a fancy shindig – it's a tribute to Black beauty's massive influence on culture and commerce. Celebrating Pioneers and Innovators...

Handshake Introduces AI Skills Studio at NYSE Event

Shaking Up the Job Market with AI Skills What's shaking things up this time around? Handshake's dramatic unveiling of its AI Skills Studio, that's what. While the world spins on its financial axis, Handshake's showing up with a toolkit that's not just geeky gobbledygook. They're dead set on prepping job seekers with the nitty-gritty of AI know-how hosted in a rather...

Matchi Debuts Protein-Packed Matcha Lattes in Cans

A New Twist on Protein Beverages Today, Matchi Global LLC is rolling out something new and bold: canned protein matcha lattes. It's not just another protein shake disguised in green robes. Oh no, this is a straight-up attempt to mesh pure ceremonial-grade matcha with a full 20 grams of complete filtered milk protein. And they’re delivering it all without any of those...

Dr. Sarah Leary Leads CBTN's Growth in Pediatric Oncology

Pioneering Leadership for Children's Brain Tumor Network In a world where every advance in pediatric oncology can make a measurable difference, the Children's Brain Tumor Network (CBTN) has just unveiled quite the ace up its sleeve: Dr. Sarah Leary. She's stepping in as Co-Chair of its Executive Board, taking the reins alongside Brian Rood, MD. With extensive experience...

Gun Violence Expo Aims for National Impact in Chicago

Converging Minds at the Chicago Gun Violence Expo In a city known for its resilience amid diverse challenges, the National Gun Violence Prevention Expo is stepping into the spotlight. With all eyes on Chicago from September 24 to 26, this isn't just another event—it’s a clarion call for action. Uniting Influential Voices When you've got former NFL stars like Matt...

Holland America Overhauls Half Moon Cay Offerings

A Fresh Chapter for Half Moon Cay Mark it down, folks—Holland America Line is shaking things up over at RelaxAway, Half Moon Cay. The cruise line, known for its deep roots in premium cruising, is pouring resources into its private island playground to celebrate its 30th anniversary in 2027. And the timing couldn't be more calculated, what with peak cruise season around...

iFranchise Holds Top Spot in Consulting for 8 Years

iFranchise's Unyielding Dominance in Franchise Consulting Five seconds in the franchise game, and you'd know that staying on top is a grind. But when you're iFranchise Group, it seems like the eighth time is the charm—if there ever was a need for luck. These folks have secured the number one spot in Entrepreneur magazine's Top Franchise Suppliers ranking yet again....

FBI Vet Marcus Thomas Joins Re-fined Nonprofit Board

Remember the days when the FBI felt like a mythical fortress of surveillance and high-tech wizardry? Today, we're seeing one of its key veterans, Marcus Thomas, take a different path—a path that's as gritty and necessary as any Wall Street hustle. He's jumping onto the board of Re-fined, a Denver nonprofit aiming to give survivors of sexual exploitation and human...

TerraMaster 725 NAS Unveils AI-Era Storage Solutions

Tech Giants and Pioneers Rejoice Strap in, because TerraMaster just waved the green flag on their brand-new 725 Series Xeon Rackmount NAS, and it's high time the data storage world got a shake-up. Picture this: we're in the throes of an AI boom, and companies have data needs that gobble up yesterday's solutions with the hunger of a black hole. Well, enter TerraMaster's...

Partners International Launches CareerPath for Youth

A Fresh Start for Young Careers with CareerPath You remember the time in life when we thought just having a degree meant something? Well, the game’s changed, and now it’s a twisted jungle where young folks struggle to find their footing. Partners International, a name I’m no stranger to—known for their human capital wizardry—seems to have noticed this chaotic...